Amgen SVP granted 1,876 shares in Form 4

Amgen Inc. senior vice president of business development Rachna Khosla received an equity award of 1,876 shares of common stock on March 3, 2026, reported as a grant, award, or other acquisition with no purchase price.

Rhea-AI Filing Summary

Amgen Inc. senior vice president of business development Rachna Khosla received an equity award of 1,876 shares of common stock on March 3, 2026, reported as a grant, award, or other acquisition with no purchase price. After this award, her directly held common stock position increased to 8,972 shares.

This total includes 107 dividend equivalents credited under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.

Insider Trade Summary

Grant/Award: 1,876 shares

Grant/Award 1 txn

Insider Khosla Rachna

Role SVP, Business Development

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,876	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,972 shares (Direct)

Footnotes (1)

1. F1. These shares include 107 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) report for Rachna Khosla?

Amgen reported that SVP of business development Rachna Khosla received an equity award of 1,876 shares of common stock. The transaction was classified as a grant or other acquisition, with no purchase price, increasing her directly held position to 8,972 shares after the award.

How many Amgen (AMGN) shares does Rachna Khosla hold after this Form 4 filing?

Following the March 3, 2026 equity award, Rachna Khosla directly holds 8,972 shares of Amgen common stock. This figure reflects the newly granted 1,876 shares and includes shares tied to dividend equivalents associated with her unvested restricted stock units under Amgen’s equity incentive plan.

What does the Form 4 say about dividend equivalents for Amgen (AMGN) shares?

The Form 4 notes that 107 dividend equivalents were credited under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These dividend equivalents attach to unvested RSUs and pay out in Amgen common stock on a one-to-one basis as awards vest, plus cash for any fractional share amounts.

Was the Amgen (AMGN) insider transaction a market purchase or a grant?

The transaction for Rachna Khosla was a grant or other acquisition, not a market purchase. It is coded as an award of 1,876 shares at a reported price of $0.0000 per share, reflecting compensation in stock under Amgen’s equity incentive arrangements rather than an open-market buy.

What role does Rachna Khosla hold at Amgen (AMGN) in this Form 4?

In this Form 4, Rachna Khosla is identified as an officer of Amgen serving as senior vice president of business development. Her reported transaction involves a stock grant of 1,876 Amgen common shares, which is part of her compensation and governed by the company’s equity incentive plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 08:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khosla Rachna

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		1,876	A	$0	8,972(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 107 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Rachna Khosla	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.